The findings of a new small study suggest that a treatment for acute COVID-19 infection is also effective against long COVID. The study evaluated the benefits of monoclonal antibodies and indicated that millions of Americans suffering from long COVID may finally find relief.
Published in the American Journal of Emergency Medicine, the study found that three patients from Florida fully – and suddenly – recovered from long COVID after receiving the monoclonal antibody cocktail Casirivimab/Imdevimab (Regeneron).
The study co-author, Dr. Paul Pepe, stated that they were impressed by the speed and completeness of the recoveries. All three patients experienced significant improvement and in some cases, complete resolution of symptoms following treatment with monoclonal antibodies.
One 63-year-old patient from Florida, who developed long COVID after a mild case of COVID-19 in 2020, described her symptoms as extreme fatigue, chest pain, and shortness of breath. After receiving Regeneron preventively in October 2021, she noticed a significant improvement after just a few days, followed by a complete recovery within a week.
The study, led by Dr. Aileen Marty, proposed several theories on how monoclonal antibodies may help in the treatment of long COVID, including boosting the body’s ability to fight residual viruses and neutralizing dysfunctional antibodies that may be causing symptoms.
The researchers plan to enroll volunteers with severe long COVID in a registry to further study the efficacy of monoclonal antibodies. Additionally, ongoing investigations are looking into the effectiveness of other monoclonal antibodies for the treatment of long COVID.
The patients who responded to Regeneron reported a return to their pre-COVID lifestyles, with some even experiencing temporary relief from their symptoms after receiving the COVID-19 vaccine. The study provides hope and insight for future treatments of long COVID.